Valenti V - Search Results

1

Olaratumab-induced Biomarker Modulation in Sarcomas-Letter.

Valenti V, Carmona-Bayonas A, Jimenez-Fonseca P, Salazar R. Valenti V, et al. Mol Cancer Ther. 2021 Oct;20(10):2093. doi: 10.1158/1535-7163.MCT-21-0413. Mol Cancer Ther. 2021. PMID: 34607901 No abstract available.

2

Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation.

Salazar R, Solá C, Maroto P, Tabernero JM, Brunet J, Verger G, Valentí V, Cancelas JA, Ojeda B, Mendoza L, Rodríguez M, Montesinos J, López-López JJ. Salazar R, et al. Among authors: valenti v. Bone Marrow Transplant. 1999 Jan;23(1):27-33. doi: 10.1038/sj.bmt.1701520. Bone Marrow Transplant. 1999. PMID: 10037047

3

Rifampin does not improve the efficacy of quinolone antibacterial prophylaxis in neutropenic cancer patients: results of a randomized clinical trial.

Gomez-Martin C, Solá C, Hornedo J, Perea S, Lumbreras C, Valentí V, Arcediano A, Rodriguez M, Salazar R, Cortés-Funes H, Hidalgo M. Gomez-Martin C, et al. Among authors: valenti v. J Clin Oncol. 2000 May;18(10):2126-34. doi: 10.1200/JCO.2000.18.10.2126. J Clin Oncol. 2000. PMID: 10811678 Clinical Trial.

4

A phase I clinical and pharmacokinetic study of paclitaxel and docetaxel given in combination in patients with solid tumours.

Izquierdo MA, García M, Pontón JL, Martínez M, Valentí V, Navarro M, Gil M, Cardenal F, Mesía R, Pérez X, Salazar R, Germà-Lluch JR. Izquierdo MA, et al. Among authors: valenti v. Eur J Cancer. 2006 Aug;42(12):1789-96. doi: 10.1016/j.ejca.2005.10.031. Epub 2006 Jun 5. Eur J Cancer. 2006. PMID: 16750622 Clinical Trial.

5

Increased survival time or better quality of life? Trade-off between benefits and adverse events in the systemic treatment of cancer.

Valentí V, Ramos J, Pérez C, Capdevila L, Ruiz I, Tikhomirova L, Sánchez M, Juez I, Llobera M, Sopena E, Rubió J, Salazar R. Valentí V, et al. Clin Transl Oncol. 2020 Jun;22(6):935-942. doi: 10.1007/s12094-019-02216-6. Epub 2019 Sep 26. Clin Transl Oncol. 2020. PMID: 31559581

6

First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis.

García-Alfonso P, Díaz-Rubio E, Abad A, Carrato A, Massutí B, Ortiz-Morales MJ, Manzano Mozo JL, Muñoz A, Durán G, Sastre J, Safont MJ, Ferreiro R, Rivera F, González E, Valladares-Ayerbes M, Grávalos C, Alonso-Orduña V, Viéitez JM, Yubero A, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD). García-Alfonso P, et al. Drugs Aging. 2021 Mar;38(3):219-231. doi: 10.1007/s40266-021-00834-w. Epub 2021 Feb 22. Drugs Aging. 2021. PMID: 33615402 Free PMC article.

7

Bayesian interpretation of the ESMO guideline for localized colorectal cancer: a better IDEA.

Carmona-Bayonas A, Jimenez-Fonseca P, Valenti V, Salazar R. Carmona-Bayonas A, et al. Among authors: valenti v. Ann Oncol. 2021 Jul;32(7):938-939. doi: 10.1016/j.annonc.2021.03.003. Epub 2021 Mar 16. Ann Oncol. 2021. PMID: 33741443 Free article. No abstract available.

8

SUNRISE-DI study. The daily sunrise is easier to predict than the benefit of adjuvant treatment in colon cancer.

Carmona-Bayonas A, Valentí V, Jiménez-Fonseca P, Salazar R. Carmona-Bayonas A, et al. Among authors: valenti v. ESMO Open. 2021 Aug;6(4):100205. doi: 10.1016/j.esmoop.2021.100205. Epub 2021 Jul 7. ESMO Open. 2021. PMID: 34242967 Free PMC article. No abstract available.

9

Fooled by Randomness. The Misleading Effect of Treatment Crossover in Randomized Trials of Therapies with Marginal Treatment Benefit.

Valentí V, Jiménez-Fonseca P, Msaouel P, Salazar R, Carmona-Bayonas A. Valentí V, et al. Cancer Invest. 2022 Feb;40(2):184-188. doi: 10.1080/07357907.2021.2020281. Epub 2021 Dec 27. Cancer Invest. 2022. PMID: 34919008

10

Is short-course radiotherapy and total neoadjuvant therapy the new standard of care in locally advanced rectal cancer? A sensitivity analysis of the RAPIDO clinical trial.

Jimenez-Fonseca P, Salazar R, Valenti V, Msaouel P, Carmona-Bayonas A. Jimenez-Fonseca P, et al. Among authors: valenti v. Ann Oncol. 2022 Aug;33(8):786-793. doi: 10.1016/j.annonc.2022.04.010. Epub 2022 Apr 22. Ann Oncol. 2022. PMID: 35462008 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

527 results

Search Page